Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 03, 2022 16:01 ET | Source: Ventyx Biosciences, Inc.

Ventyx Biosciences Reports Third Quarter 2022 Financial Results and Highlights Recent Corporate Progress

We are on track to initiate Phase 2 trials of our allosteric TYK2 inhibitor VTX958 in psoriasis, Crohn’s disease and psoriatic arthritis this quarter Cash, cash equivalents and marketable...
October 27, 2022 16:05 ET | Source: Ventyx Biosciences, Inc.

Ventyx Biosciences to Report Third Quarter 2022 Financial Results on November 3, 2022

ENCINITAS, Calif., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX), (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that...
October 27, 2022 09:00 ET | Source: Ventyx Biosciences, Inc.

Ventyx Biosciences to Participate in Three Upcoming Investor Conferences

ENCINITAS, Calif., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX), (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that...
September 19, 2022 08:00 ET | Source: Ventyx Biosciences, Inc.

Ventyx Biosciences Announces $176.6 Million Private Placement of Common Stock

ENCINITAS, Calif., Sept. 19, 2022 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that...
August 29, 2022 16:05 ET | Source: Ventyx Biosciences, Inc.

Ventyx Biosciences to Participate in Two Upcoming Investor Conferences

ENCINITAS, Calif., Aug. 29, 2022 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX), (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that...
August 15, 2022 16:05 ET | Source: Ventyx Biosciences, Inc.

Ventyx Biosciences Reports Second Quarter 2022 Financial Results and Highlights Recent Corporate Progress

VTX958, our allosteric TYK2 inhibitor, demonstrated an excellent safety profile and class-leading target coverage in Phase 1 trial Cash, cash equivalents and marketable securities of $258.4 million...
August 15, 2022 16:01 ET | Source: Ventyx Biosciences, Inc.

Ventyx Biosciences Announces Positive Topline Phase 1 Data for Its Selective Allosteric TYK2 Inhibitor VTX958

VTX958 was well-tolerated across all SAD and MAD cohorts with an excellent safety profile Class-leading target coverage, with TYK2 IC50 and IC90 coverage up to 24 hours Robust dose-dependent...
August 11, 2022 16:05 ET | Source: Ventyx Biosciences, Inc.

Ventyx Biosciences to Report Topline Results from the Phase 1 trial of its TYK 2 Inhibitor VTX958 and Second Quarter 2022 Financial Results on August 15, 2022

ENCINITAS, Calif., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX), (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that...
June 29, 2022 08:00 ET | Source: Ventyx Biosciences, Inc.

Ventyx Biosciences Announces Positive Topline Phase 1 Data for its Peripheral NLRP3 Inhibitor VTX2735

Excellent safety, tolerability and pharmacokinetic profile Robust dose-dependent target engagement as measured by ex vivo IL-1β release assay Phase 2 trial planned in CAPS patients to efficiently...
June 01, 2022 08:00 ET | Source: Ventyx Biosciences, Inc.

Ventyx Biosciences to Participate in the Jefferies Healthcare Conference

ENCINITAS, Calif., June 01, 2022 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX), (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that...